Phil Young
Prior to joining USVP in 1990, Phil spent four years with Concord Partners, Dillon Read's venture capital operation in Palo Alto. With a specialty in... the medical device industry, Phil has watched the evolution of new methodologies, such as the emergence of minimally-invasive treatments, into increasingly diverse and pervasive applications. Like other USVP partners, Phil arrived with extensive operating experience. He was President and CEO of Oximetrix, a manufacturer of critical care instruments and disposables, where he spent eight years growing the privately-held venture-backed company from $1 million in revenues to nearly $50 million. Prior to Oximetrix, Phil spent six years at New Court Securities in venture capital and corporate finance, two years as a management consultant with McKinsey & Co., and six years on Admiral Rickover's project management staff at the Atomic Energy Commission. He has represented USVP on the boards of Aerogen, CardioThoracic Systems, CardioVascular Imaging Systems, CoCensys, Compugen, FemRx, Penederm, 3Dfx Interactive, Vical and Xoma-all of which became public companies, and on the boards of RelayHealth and St. Francis Medical Technologies which were acquired. Currently he sits on the boards of Zoran, a public company, and privately-held Aptus Endosystems, Bayhill Therapeutics, Claria, Dotomi, Synarc, Talima Therapeutics, and Timi3 Systems. He also serves on the Board of Trustees of Cornell University and as Chairman of the Board of eCornell, the university's online distance learning subsidiary. Phil earned a B.M.E. from Cornell University with High Distinction, an M.S. in Engineering Physics from George Washington University, and an M.B.A. with High Distinction from Harvard, where he was a Baker Scholar.
more